Hospital
VHS Detroit Receiving Hospital INC
VHS Detroit Receiving Hospital INC was paid $60.48M by Medicaid between Jan 2018 and Dec 2024, across 297 billing codes. Its largest line is 99285, emergency room visit (most serious) — 22% of everything it billed.
33Billing provider infoVHS DETROIT RECEIVING HOSPITAL INC
DETROIT, MI 48201
DETROIT, MI 48201
33aNPI1619289998assigned 07/02/2010
33bProvider typeGeneral Acute Care Hospital
28Total paid$60.48M
24GClaims1,534,565
24DCodes billed297
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Michigan
Rank by total paid#19 of 86
Median peer was paid$21.55M
This provider vs. median2.8×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 288,482 | $11.04M | |
| 2019 | 257,756 | $9.88M | |
| 2020 | 220,877 | $7.98M | |
| 2021 | 217,979 | $8.74M | |
| 2022 | 202,215 | $8.21M | |
| 2023 | 204,681 | $7.97M | |
| 2024incomplete | 142,575 | $6.65M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 22% | 38,382 | 36,151 | $13.25M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 19% | 58,915 | 55,479 | $11.61M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 17% | 85,875 | 76,400 | $10.46M |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 11% | 112,939 | 97,981 | $6.88M |
| G0378 | Hospital observation service, per hour | 7.5% | 10,216 | 9,511 | $4.52M |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 3.5% | 27,718 | 25,972 | $2.09M |
| 20610 | 1.4% | 2,801 | 2,771 | $855K | |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 1.4% | 9,966 | 8,889 | $838K |
| 71046 | Radiologic examination, chest; 2 views | 1.1% | 23,905 | 22,837 | $682K |
| 95811 | <1% | 1,105 | 1,100 | $556K | |
| 71045 | Radiologic examination, chest; single view | <1% | 17,178 | 16,350 | $528K |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 922 | 919 | $459K |
285 more codes
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 18,985 | $428K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 3,666 | $422K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 6,989 | $405K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 10,258 | $399K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 5,413 | $375K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 4,956 | $353K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 4,963 | $304K |
| 80061 | Lipid panel | <1% | 5,189 | $297K |
| G0390 | Trauma response team associated with hospital critical care service | <1% | 1,450 | $296K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 2,258 | $269K |
| 70486 | <1% | 2,502 | $255K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 6,645 | $248K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 33,780 | $195K |
| 29581 | <1% | 2,321 | $181K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 59,296 | $149K |
| 97161 | <1% | 2,044 | $134K | |
| 76801 | <1% | 2,606 | $133K | |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 1,247 | $115K |
| 99218 | <1% | 359 | $113K | |
| 10060 | <1% | 1,162 | $112K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 10,008 | $102K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 10,002 | $94K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 10,278 | $85K |
| 82962 | <1% | 44,692 | $78K | |
| 93971 | <1% | 1,631 | $75K | |
| 29125 | <1% | 1,176 | $75K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 3,037 | $72K |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | <1% | 621 | $69K |
| 97602 | <1% | 539 | $67K | |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 2,144 | $61K |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 120 | $60K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 161 | $58K |
| 84484 | <1% | 21,008 | $56K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 1,219 | $53K |
| 29580 | <1% | 365 | $44K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 7,570 | $42K |
| 76830 | Ultrasound, transvaginal | <1% | 943 | $42K |
| 86885 | <1% | 8,492 | $42K | |
| 93970 | <1% | 456 | $41K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 986 | $41K |
| 81025 | <1% | 25,718 | $41K | |
| 97165 | <1% | 1,446 | $39K | |
| 41899 | Unlisted procedure, dentoalveolar structures | <1% | 32 | $37K |
| 86780 | <1% | 4,348 | $35K | |
| 29405 | <1% | 112 | $35K | |
| 72100 | <1% | 4,338 | $33K | |
| 73610 | <1% | 8,112 | $31K | |
| 80053 | Comprehensive metabolic panel | <1% | 11,962 | $30K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 1,632 | $29K |
| 73030 | <1% | 5,320 | $27K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 635 | $27K |
| 73562 | <1% | 7,894 | $27K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 14,316 | $27K |
| 73130 | <1% | 8,007 | $26K | |
| 83735 | <1% | 44,372 | $26K | |
| 12011 | <1% | 728 | $24K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 6,672 | $24K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 28,831 | $23K |
| 72110 | <1% | 3,111 | $22K | |
| 12002 | <1% | 510 | $21K | |
| 12001 | <1% | 991 | $20K | |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 61 | $20K |
| 73630 | <1% | 6,519 | $18K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 2,646 | $18K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 28,047 | $17K |
| 73564 | <1% | 3,914 | $17K | |
| 72170 | <1% | 6,568 | $17K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 4,160 | $16K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 5,986 | $16K |
| 29515 | <1% | 126 | $15K | |
| 97597 | <1% | 122 | $15K | |
| 90472 | Immunization administration, each additional vaccine (list separately) | <1% | 1,040 | $15K |
| G0121 | Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | <1% | 36 | $15K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 3,211 | $15K |
| 72050 | <1% | 1,380 | $14K | |
| 90674 | <1% | 734 | $14K | |
| 73110 | <1% | 4,498 | $14K | |
| 73590 | <1% | 3,979 | $13K | |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 26 | $13K |
| 90686 | <1% | 832 | $12K | |
| 73502 | <1% | 4,405 | $12K | |
| 73560 | <1% | 2,251 | $12K | |
| 72070 | <1% | 1,915 | $11K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 7,664 | $11K |
| 64400 | <1% | 82 | $11K | |
| 85027 | <1% | 41,490 | $11K | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 2,394 | $11K |
| 82728 | <1% | 2,236 | $10K | |
| 72040 | <1% | 1,228 | $10K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 27,139 | $9K |
| 70496 | <1% | 58 | $8K | |
| 84100 | <1% | 5,094 | $8K | |
| G0008 | Administration of influenza virus vaccine | <1% | 910 | $8K |
| 73080 | <1% | 2,309 | $8K | |
| 82803 | <1% | 833 | $8K | |
| 70498 | <1% | 108 | $7K | |
| 83880 | <1% | 4,484 | $7K | |
| 81001 | <1% | 20,473 | $6K | |
| 90670 | <1% | 57 | $6K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 110 | $6K |
| 90834 | Psychotherapy session, about 45 minutes | <1% | 128 | $6K |
| 97116 | <1% | 1,844 | $6K | |
| 86900 | <1% | 10,192 | $6K | |
| P9016 | Red blood cells, leukocytes reduced, each unit | <1% | 50 | $6K |
| 73090 | <1% | 1,952 | $6K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 1,934 | $5K |
| 73700 | <1% | 82 | $5K | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 8,459 | $5K |
| 83690 | <1% | 11,257 | $5K | |
| 82550 | <1% | 2,068 | $5K | |
| 43235 | <1% | 13 | $5K | |
| 84703 | <1% | 8,510 | $5K | |
| J1815 | Injection, insulin, per 5 units | <1% | 374 | $5K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 266 | $5K |
| 85730 | <1% | 15,416 | $5K | |
| 16020 | <1% | 1,894 | $4K | |
| 87631 | <1% | 947 | $4K | |
| 82607 | <1% | 1,400 | $4K | |
| 85610 | <1% | 15,747 | $4K | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 4,281 | $4K |
| Q3014 | Telehealth originating site facility fee | <1% | 267 | $4K |
| 73140 | <1% | 1,127 | $4K | |
| 86803 | <1% | 918 | $4K | |
| 85652 | <1% | 1,451 | $4K | |
| J2704 | Injection, propofol, 10 mg | <1% | 5,950 | $4K |
| 88304 | <1% | 236 | $3K | |
| 73552 | <1% | 1,872 | $3K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 8,637 | $3K |
| 71101 | <1% | 453 | $3K | |
| 86901 | <1% | 10,192 | $3K | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 10,809 | $3K |
| 84439 | <1% | 1,215 | $3K | |
| 90750 | <1% | 24 | $3K | |
| 10061 | <1% | 15 | $3K | |
| 97166 | <1% | 53 | $3K | |
| 83605 | <1% | 2,803 | $3K | |
| 81003 | <1% | 10,671 | $3K | |
| 29075 | <1% | 15 | $3K | |
| 85379 | <1% | 2,526 | $3K | |
| 73060 | <1% | 1,136 | $2K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 9,168 | $2K |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 3,681 | $2K |
| 82805 | <1% | 465 | $2K | |
| C8929 | Transthoracic echocardiography with contrast, or without contrast followed by with contrast, real-time with image documentation (2d), includes m-mode recording, when performed, complete, with spectral doppler echocardiography, and with color flow doppler echocardiography | <1% | 38 | $2K |
| 36430 | <1% | 15 | $2K | |
| 74022 | <1% | 768 | $2K | |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 2,654 | $2K |
| 87040 | <1% | 1,266 | $2K | |
| 87077 | <1% | 1,315 | $2K | |
| 84702 | <1% | 3,464 | $2K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 720 | $2K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 1,070 | $2K |
| 90715 | <1% | 7,342 | $2K | |
| 72131 | <1% | 95 | $2K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 8,786 | $2K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 1,840 | $1K |
| 90732 | <1% | 13 | $1K | |
| 87340 | <1% | 1,798 | $1K | |
| 82248 | <1% | 6,411 | $1K | |
| 0011A | <1% | 48 | $1K | |
| 73600 | <1% | 502 | $1K | |
| 82043 | <1% | 834 | $1K | |
| 72128 | <1% | 65 | $1K | |
| 86140 | <1% | 1,750 | $1K | |
| 85046 | <1% | 1,230 | $1K | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 2,252 | $1K |
| 83540 | <1% | 686 | $1K | |
| 96367 | <1% | 73 | $1K | |
| G0009 | Administration of pneumococcal vaccine | <1% | 81 | $1K |
| 29130 | <1% | 251 | $989.63 | |
| 84460 | <1% | 8,414 | $959.21 | |
| 84450 | <1% | 8,486 | $931.18 | |
| 84132 | <1% | 1,723 | $930.75 | |
| 87467 | <1% | 279 | $897.51 | |
| Q2037 | Influenza virus vaccine, split virus, when administered to individuals 3 years of age and older, for intramuscular use (fluvirin) | <1% | 64 | $894.39 |
| G0123 | Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, screening by cytotechnologist under physician supervision | <1% | 81 | $844.24 |
| 86850 | <1% | 1,672 | $741.84 | |
| 82247 | <1% | 6,519 | $713.75 | |
| 74018 | <1% | 211 | $710.82 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 16,298 | $704.70 |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 2,079 | $697.65 |
| 74021 | <1% | 100 | $690.86 | |
| 84075 | <1% | 6,465 | $686.75 | |
| 80074 | <1% | 77 | $651.84 | |
| 87070 | <1% | 500 | $642.57 | |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 2,281 | $606.56 |
| 74019 | <1% | 206 | $590.77 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 16,580 | $563.14 |
| 83550 | <1% | 300 | $554.31 | |
| J1953 | Injection, levetiracetam, 10 mg | <1% | 418 | $513.08 |
| 82330 | <1% | 504 | $472.84 | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 318 | $463.76 |
| 82570 | <1% | 369 | $446.29 | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 981 | $445.95 |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 589 | $426.63 |
| 82746 | <1% | 164 | $423.98 | |
| 82150 | <1% | 607 | $394.55 | |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 7,678 | $369.79 |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 217 | $357.60 |
| 86706 | <1% | 100 | $355.87 | |
| 73620 | <1% | 49 | $342.63 | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 8,463 | $339.89 |
| 90656 | <1% | 16 | $326.12 | |
| A9270 | Non-covered item or service | <1% | 111,772 | $319.30 |
| 83090 | <1% | 48 | $314.40 | |
| S0028 | Injection, famotidine, 20 mg | <1% | 832 | $300.00 |
| 86923 | <1% | 81 | $296.33 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 10,310 | $295.28 |
| 87205 | <1% | 476 | $283.15 | |
| 80185 | <1% | 375 | $282.41 | |
| J1631 | Injection, haloperidol decanoate, per 50 mg | <1% | 222 | $278.34 |
| 94760 | <1% | 3,971 | $256.00 | |
| 84295 | <1% | 480 | $249.63 | |
| 85014 | <1% | 569 | $249.60 | |
| 82010 | <1% | 1,438 | $234.37 | |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 103 | $228.52 |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | <1% | 1,438 | $223.41 |
| S0077 | Injection, clindamycin phosphate, 300 mg | <1% | 36 | $215.76 |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 960 | $215.01 |
| 80051 | <1% | 46 | $204.28 | |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 984 | $203.88 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 3,390 | $202.19 |
| S0020 | Injection, bupivicaine hydrochloride, 30 ml | <1% | 1,804 | $169.50 |
| J7042 | 5% dextrose/normal saline (500 ml = 1 unit) | <1% | 471 | $161.53 |
| 86704 | <1% | 37 | $160.99 | |
| 90474 | <1% | 12 | $149.15 | |
| 76937 | <1% | 40 | $147.66 | |
| 82140 | <1% | 140 | $147.09 | |
| J3415 | Injection, pyridoxine hcl, 100 mg | <1% | 202 | $135.20 |
| J3411 | Injection, thiamine hcl, 100 mg | <1% | 135 | $135.13 |
| 96376 | <1% | 6,270 | $135.04 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 3,061 | $134.65 |
| J7121 | 5% dextrose in lactated ringers infusion, up to 1000 cc | <1% | 408 | $122.52 |
| J2920 | Injection, methylprednisolone sodium succinate, up to 40 mg | <1% | 258 | $118.72 |
| 72190 | <1% | 15 | $112.47 | |
| 99396 | Periodic comprehensive preventive medicine reevaluation, established patient, 40-64 years | <1% | 12 | $108.48 |
| J2359 | Injection, olanzapine, 0.5 mg | <1% | 14 | $105.33 |
| 88312 | <1% | 51 | $103.68 | |
| 83615 | <1% | 237 | $97.22 | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 41 | $95.40 |
| J1580 | Injection, garamycin, gentamicin, up to 80 mg | <1% | 107 | $94.19 |
| 87075 | <1% | 61 | $85.42 | |
| 99201 | <1% | 49 | $82.50 | |
| C1729 | Catheter, drainage | <1% | 156 | $74.94 |
| 86141 | <1% | 14 | $66.53 | |
| 85018 | <1% | 132 | $64.23 | |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 21 | $56.10 |
| J7060 | 5% dextrose/water (500 ml = 1 unit) | <1% | 259 | $54.77 |
| 80143 | <1% | 12 | $49.68 | |
| 83655 | <1% | 15 | $42.98 | |
| J1596 | Injection, glycopyrrolate, 0.1 mg | <1% | 215 | $41.45 |
| 82040 | <1% | 134 | $31.35 | |
| 87807 | <1% | 26 | $30.96 | |
| 82272 | <1% | 385 | $29.06 | |
| 85384 | <1% | 13 | $27.36 | |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 666 | $26.42 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 59 | $26.10 |
| J2310 | Injection, naloxone hydrochloride, per 1 mg | <1% | 79 | $18.50 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 3,894 | $17.71 |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 1,230 | $14.32 |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 125 | $13.86 |
| J0295 | Injection, ampicillin sodium/sulbactam sodium, per 1.5 gm | <1% | 49 | $13.37 |
| 83037 | <1% | 42 | $10.29 | |
| J0692 | Injection, cefepime hydrochloride, 500 mg | <1% | 18 | $9.23 |
| 84156 | <1% | 12 | $7.66 | |
| 82375 | <1% | 25 | $7.47 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 4,668 | $6.49 |
| 82565 | <1% | 53 | $6.45 | |
| 84520 | <1% | 34 | $5.25 | |
| J1030 | Injection, methylprednisolone acetate, 40 mg | <1% | 12 | $4.56 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 189 | $1.16 |
| C9113 | Injection, pantoprazole sodium, per vial | 0% | 1,225 | $0.00 |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 152 | $0.00 |
| 41800 | 0% | 13 | $0.00 | |
| J3260 | Injection, tobramycin sulfate, up to 80 mg | 0% | 14 | $0.00 |
| 80076 | 0% | 12 | $0.00 | |
| Q9957 | Injection, perflutren lipid microspheres, per ml | 0% | 13 | $0.00 |
| J7070 | Infusion, d5w, 1000 cc | 0% | 13 | $0.00 |
| 90632 | 0% | 109 | $0.00 | |
| C1769 | Guide wire | 0% | 27 | $0.00 |
| J1790 | Injection, droperidol, up to 5 mg | 0% | 952 | $0.00 |
| J2470 | Injection, pantoprazole sodium, 40 mg | 0% | 108 | $0.00 |
| 76604 | 0% | 13 | $0.00 | |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | 0% | 63 | $0.00 |
| 76870 | 0% | 14 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialBROW, BEN (CFO)
| Provider | Location | Paid |
|---|---|---|
| VHS Harper-Hutzel Hospital INC | Detroit, MI | $76.70M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.